Nanordica Medical Raises €1.6M to Push Antibiotic-Free Wound Care

Estonian medtech Nanordica Medical has closed a €1.6 million round to bring its Premotiv antibiotic-free wound dressing to European patients. The bet is that chronic wound care is bottlenecked by the absence of clinical evidence on existing products.

The Tallinn-based company posted the €1.6M funding announcement on June 10, the same week the wound-care market intelligence platform SmartTRAK named it among four advanced wound-dressing companies to watch. The round was led by Estonian cleantech and deep tech fund 2C Ventures, with participation from existing investors Specialist VC, Superangel, Amalfi, the Health Founders syndicate led by Erki Mölder, and the EstBAN syndicate led by Heidi Kakko and Martin Goroško. The €1.6 million sits alongside a €2.4 million European Innovation Council (EIC) Accelerator grant the company already holds.

The €1.6M Bet on Antibiotic-Free Wound Care

Around 100 million people worldwide live with chronic wounds that fail to heal, and more than half of those wounds become infected. Infections can cascade into sepsis, amputation, or death. Diabetic foot ulcers, the most consequential subset, are the leading cause of non-traumatic leg amputations globally, with one limb lost to diabetes every 20 seconds, a pace that has earned DFUs the label “silent killer” because their five-year mortality and treatment costs are comparable to cancer.

Systemic antibiotics are the only treatment that diabetic foot ulcer guidelines currently endorse for infected wounds, but they often fail to reach the wound site at sufficient concentrations. Their use is also tightening as antimicrobial resistance spreads. Existing antibacterial dressings fill the gap poorly: most lack the clinical evidence to earn a guideline recommendation, and many rely on high concentrations of agents that damage healthy skin cells and slow healing. Nanordica’s wager is that the field will reward the first product to clear both bars at the same time.

The Clinical Numbers Behind the Bet

The bet rests on a peer-reviewed dataset. Nanordica’s Premotiv dressing cut wound area by 43% after one week in a Journal of Wound Care randomized controlled trial, against 13% for standard silver dressings. That comparison is the first head-to-head reading the field has on the same endpoint.

Key figures from the pilot and the broader rollout:

• 30 patients in the published pilot study
• 120+ patients in the ongoing multicentre, double-blind, randomized trial
• €2.4M prior EIC Accelerator grant funding the regulatory and clinical work

The size of that gap, on the same endpoint, is the lever the company is leaning on. The larger trial is running across European sites and is one of the largest of its kind in diabetic foot ulcer care. Prof. Dr. José Luis Lázaro Martínez, Chair of the Diabetic Foot Committee of the European Wound Management Association and the principal investigator on the multicentre trial, has framed the prize bluntly: a clean read-out would push antibacterial dressings supported by clinical evidence into the next revision of the DFU treatment guidelines. That is the step that puts a product on reimbursement lists and standard hospital formularies.

Antimicrobial resistance is one of the defining healthcare challenges of this decade and most wound care products are making it worse. Nanordica has built a clinically proven alternative that doesn’t rely on antibiotics, doesn’t compromise healing, and leaves a significantly smaller environmental footprint. We backed the team because they had both the science and the conviction to see this through.

That is Martin Koppel, Founding Partner of 2C Ventures, speaking in the funding announcement first reported by tech.eu. The “most wound care products are making it worse” line is the contrarian edge of the bet: Nanordica is positioning itself as much against the existing antibacterial dressing category as against untreated infection.

Who Is Backing the Bet

2C Ventures, the lead investor on the €1.6M round, is an Estonian fund run by Martin Koppel, the co-founder and former CEO of mobile payments company Fortumo. The firm launched a €50 million fund to back sustainability and deep tech startups in the Baltic and Nordic regions. For Koppel, the wound-care case folds the antimicrobial resistance crisis into a single bet on a company that has data, not just chemistry.

The full list of participants in the €1.6M round:

• 2C Ventures (lead)
• Specialist VC (existing investor)
• Superangel (existing investor)
• Amalfi (existing investor)
• Health Founders syndicate, led by Erki Mölder
• EstBAN syndicate, led by Heidi Kakko and Martin Goroško

The investor mix matters because each name represents a different checkbook: a sector specialist, two Estonian generalist angels, a healthcare-focused syndicate, and the country’s main business angel network. None of the participants are framing this as a moonshot; the company is selling into a market that already spends on chronic wound care and is looking for products that fit the next iteration of the guidelines.

What Premotiv Actually Does

Premotiv is a sterile, single-use dressing whose wound contact layer is built from natural silk nanofibers. Nanordica’s patented Premotiv technology pairs antimicrobial action with skin-cell safety, the trade-off that has kept most antibacterial dressings off the guideline-recommended list. The company hasn’t published a full mechanism, but the clinical data and the company’s own materials frame it as a category that treats infection and promotes healing in parallel.

The company has worked through the operational checklist for a CE-marked launch. ISO 13485:2016 certification is in place for the quality management system, a European patent has been granted, and the animal-health product serves as a working commercial proof point.

Where the Money Goes

CEO and co-founder Olesja Bondarenko, a spin-off founder from Estonia’s National Institute of Chemical Physics and Biophysics, is running three workstreams in parallel. The multicentre diabetic foot ulcer trial will run to completion to generate the evidence base for reimbursement. The CE marking file is being finalised for European commercial launch. And the commercial team is being built out for a market entry timed to the regulatory finish line.

The trade is that a clean read on the larger trial, plus a CE mark in hand, repositions Premotiv from a pilot-stage innovation into a guideline-eligible product. That is the step at which hospital procurement, national reimbursement bodies, and wound-care specialists start to look at a dressing differently. Bondarenko has framed the next data read-out, not the next funding round, as the milestone the team is working toward.

The new capital also funds a commercial team being built out in advance of the launch, timed to the regulatory finish line. Ravimus Vet has been on sale in six countries since 2023, providing the company with a working distribution footprint.

CE marking is the regulatory step that allows the dressing to be sold in Europe. The clinical trial data is the evidence base for reimbursement and guideline recommendations. The round is structured to fund both workstreams in parallel.

The Antimicrobial Resistance Stakes

The clinical and commercial case for Premotiv sits inside a larger pressure on the wound-care market. The World Health Organization lists antimicrobial resistance among the top global public health threats, and chronic wounds are one of the heaviest antibiotic-using indications in hospital care. A dressing that clears infection without contributing to that resistance pool, and that carries randomized clinical data to prove it, has a route into guidelines that silver-iodine and chlorhexidine dressings have struggled to find. The same pressure is pulling capital into adjacent European AMR startups such as iFAST Diagnostics, a UK antibiotic-choice time startup.

That is also why the round drew five different checkbooks across a syndicate, with no single lead claiming the whole bet. The narrower winners from this outcome are Nanordica and the clinical sites enrolling into its trial, and the broader beneficiaries are health systems looking for an evidence-backed lever against AMR. The losers, if the larger trial reads out cleanly, are the silver-dressing and antibiotic-heavy protocols that have dominated DFU care, and the investors still backing them.

This financing round will enable us to complete a large randomised clinical study, strengthening the economic case for Premotiv and finalise CE marking for commercial launch in Europe. Our clinical data suggest that Premotiv helps wounds heal faster by managing infection without compromising the natural healing process. Faster healing has the potential to reduce complications, lower treatment costs and improve outcomes for patients with chronic wounds.

That is Bondarenko, in the announcement. The next milestone is the multicentre trial read-out, and Nanordica has framed the data, not the next round, as the commercial pace-setter.

Frequently Asked Questions

What is Premotiv?

Premotiv is Nanordica Medical’s patented wound-dressing technology. The dressing is built around a natural silk nanofiber contact layer that fights infection and supports skin-cell repair at the same time, a combination the company says existing silver-based dressings struggle to deliver.

How much did Nanordica Medical raise?

Nanordica Medical closed a €1.6 million round on June 10, 2026. Estonian cleantech and deep tech fund 2C Ventures led the deal, with existing Estonian backers Specialist VC, Superangel, Amalfi, and two syndicates joining in. The Health Founders syndicate is led by Erki Mölder; the EstBAN syndicate by Heidi Kakko and Martin Goroško.

What clinical evidence supports the dressing?

In a randomized trial of 30 diabetic foot ulcer patients, Premotiv produced a 43% reduction in wound area after one week of treatment, against 13% for standard silver dressings. The study, published in the Journal of Wound Care, is the company’s lead clinical claim. A larger multicentre, double-blind, randomized study with more than 120 patients is now in progress to support reimbursement and guideline submissions.

When will the product reach patients?

Nanordica plans to launch the human wound dressing in Europe after securing CE marking. The new capital funds the larger trial and the regulatory work needed for that approval. The company hasn’t set a public launch date.

Why is an antibiotic-free approach important?

Diabetic foot ulcer guidelines recommend systemic antibiotics for infected wounds, but those drugs often miss therapeutic doses at the wound site, and their overuse is driving antimicrobial resistance. A dressing that can clear infection without adding to that resistance burden, backed by peer-reviewed randomized data, opens a path into the next revision of the treatment guidelines, one that silver-iodine and chlorhexidine dressings have not been able to walk down.

Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice. Statements about wound-care outcomes and clinical trial results reflect figures published in the Journal of Wound Care and in the company’s funding announcement. Readers with chronic wounds should consult a qualified healthcare professional. Figures are accurate as of the publication date.